Article thumbnail
Location of Repository

On the Action of Cyclosporine A, Rapamycin and Tacrolimus on M. avium Including Subspecies paratuberculosis

By Robert J. Greenstein, Liya Su, Ramon A. Juste and Sheldon T. Brown
Topics: Research Article
Publisher: Public Library of Science
OAI identifier: oai:pubmedcentral.nih.gov:2427180
Provided by: PubMed Central

Suggested articles

Citations

  1. (1895) Ein eigenthumlicher fall von tuberculose beim rind ( A particular case of tuberculosis in a cow). Dtsch Zeitschr Tiermed,
  2. (2001). A frameshift mutation in NOD2 associated with a susceptability to Crohn’s disease.
  3. (2007). A Novel Multi-Antigen Virally Vectored Vaccine against Mycobacterium avium Subspecies paratuberculosis.
  4. (1997). A study on the effectiveness and safety of the WHO/MDT regimen in the northeast of Thailand; a prospective study,
  5. (1993). Activities of fluoroquinolone, macrolide, and aminoglycoside drugs combined with inhibitors of glycosylation and fatty acid and peptide biosynthesis against Mycobacterium avium.
  6. (1992). Activity of clarithromycin compared with those of other drugs against Mycobacterium paratuberculosis and further enhancement of its extracellular and intracellular activities by ethambutol.
  7. (2006). An up-date review on individualized dosage adjustment of calcineurin inhibitors in organ transplant patients.
  8. (2005). Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement.
  9. (2001). Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn’s disease.
  10. (1976). Biological effects of cyclosporin A: a new antilymphocytic agent.
  11. (1913). Chronic intestinal enteritis.
  12. (2000). Clinical features and treatment of peristomal pyoderma gangrenosum.
  13. (1986). Confirmation of the beige mouse model for study of disseminated infection with Mycobacterium avium complex.
  14. (2002). Correlation between optimal tacrolimus doses and the graft weight in living donor liver transplantation.
  15. (2008). Cristofano A
  16. (2004). Culture of Mycobacterium avium subspecies paratuberculosis from the blood of patients with Crohn’s disease.
  17. (1997). Cyclosporin A-sensitive induction of the Epstein-Barr virus lytic switch is mediated via a novel pathway involving a MEF2 family member.
  18. (1992). Cyclosporin pharmacokinetics after intravenous and oral administration in patients with Crohn’s disease.
  19. (2007). Cyclosporine and tacrolimus for the treatment of rheumatoid arthritis.
  20. (1994). Cyclosporine in severe ulcerative colitis refractory to steroid therapy.
  21. (2005). Detection of viable Mycobacterium avium subsp. paratuberculosis in retail pasteurized whole milk by two culture methods and PCR.
  22. (2006). Early renal benefit of rapamycin combined with reduced calcineurin inhibitor dose in pediatric heart transplantation patients.
  23. (2002). Effect of Commercial-Scale High-Temperature,S h o r t - T i m eP a s t e u r i z a t i o no nt h e Viability of Mycobacterium paratuberculosis in Naturally Infected Cows’ Milk.
  24. (1997). Effects of rapamycin, cyclosporin A, and dexamethasone on interleukin 5-induced eosinophil degranulation and prolonged survival.
  25. (2007). Efficacy of spheroplastic and cell-wall competent vaccines for Mycobacterium avium subsp. paratuberculosis in experimentally-challenged baby goats.
  26. (2004). Emerging pathogens: is Mycobacterium avium subspecies paratuberculosis zoonotic?
  27. (1987). FK506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics.
  28. (1990). Growth of Mycobacterium paratuberculosis in radiometric, Middlebrook and egg-based media.
  29. (1990). Herskowitz A
  30. (2008). Immune responses in mice to Mycobacterium avium subsp. paratuberculosis following vaccination with a novel 74F recombinant polyprotein.
  31. (2003). Immunodulation with tacrolimus (FK506): results of a prospective, open-label, non-controlled trial in patients with inflammatory bowel disease.
  32. (1994). Immunosuppressive agents in chronic severe asthma. Allergy Proc 15: 147–150. Immunosuppressants &
  33. (2000). Immunosuppressive drugs: the first 50 years and a glance forward.
  34. (1993). Influence of cyclosporine pharmacokinetics, trough concentrations, and AUC monitoring on outcome after kidney transplantation.
  35. (2007). Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial).
  36. (2003). Is Crohn’s disease caused by a mycobacterium? Comparisons with leprosy, tuberculosis, and Johne’s disease.
  37. (2000). Isolation of Mycobacterium avium subsp paratuberculosis from breast milk of Crohn’s disease patients.
  38. (1991). Long-term treatment of Crohn’s disease with cyclosporine: the effect of a very low dose on maintenance of remission.
  39. (2001). Management of tuberculosis in the United States.
  40. (2007). Medium-term results of oral tacrolimus treatment in refractory inflammatory bowel disease.
  41. (2008). Methotrexate vs. ciclosporin in psoriasis: effectiveness, quality of life and safety. A randomized controlled trial.
  42. (2005). Mycobacterium avium subspecies paratuberculosis cultured from locally and commercially pasteurized cow’s milk in the Czech Republic.
  43. (1997). Nonspecific resistance to Mycobacteria: the role of the Nramp1 gene. Behring Inst Mitt.
  44. (2007). On the Action of 5-AminoSalicylic Acid and Sulfapyridine on M. avium including Subspecies paratuberculosis.
  45. (1996). On the etiology of Crohn disease.
  46. (1996). Pharmacokinetics of the conventional and microemulsion formulations of cyclosporine in pancreas-kidney transplant recipients with gastroparesis.
  47. (1975). Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle.
  48. (1975). Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization.
  49. (1979). Rapamycin (AY-22,989), a new antifungal antibiotic. IV. Mechanism of action.
  50. (2007). Rapamycin enhances the anti-tumor effect of gemcitabine in pancreatic cancer cells.
  51. (1993). Rapamycin, a potential disease-modifying antiarthritic drug.
  52. (1995). Rapamycin, FK506 and cyclosporin A inhibit human prolactin gene expression.
  53. (1993). Rapid closure of Crohn’s disease fistulas with continuous intravenous cyclosporin A [see comments].
  54. (1986). Spheroplastic phase of mycobacteria isolated from patients with Crohn’s disease.
  55. (1992). Stutz A
  56. (2006). Tacrolimus is safe and effective in patients with severe steroid-refractory or steroid-dependent inflammatory bowel disease–a long-term follow-up.
  57. (1997). Tacrolimus. An update of its pharmacology and clinical efficacy in the management of organ transplantation.
  58. (2003). The effect of combined rapamycin/cyclosporine on the changes in pro-fibrotic gene expression that occur during the development of allograft vasculopathy in rats, compared with cyclosporine or rapamycin in isolation.
  59. (2004). The Mycobacterium avium subspecies paratuberculosis problem and its relation to the causation of Crohn disease. In:
  60. (1991). The role of cyclosporin therapy in Crohn’s disease. A review.
  61. (2008). The role of tacrolimus in renal transplantation.
  62. (2001). Therapeutic drug monitoring for immunosuppressants.
  63. (2008). Thiopurine drugs (azathioprine and 6-mercaptopurine) inhibit Mycobacterium paratuberculosis growth in vitro.
  64. (2002). Treatment of severe Crohn’s disease using antimycobacterial triple therapy–approaching a cure? Dig Liver Dis
  65. (2007). Two-year combination antibiotic therapy with clarithromycin, rifabutin, and clofazimine for Crohn’s disease.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.